Navigation Links
EGT Transfers cGMP Vector for Gene Therapy Trial
Date:7/29/2011

CHICAGO, July 29, 2011 /PRNewswire/ -- Errant Gene Therapeutics, LLC ("EGT"), a pioneering boutique drug development firm specializing in Rare Diseases, announced the transfer of its clinical grade lentiviral vector, TNS 9.55.3, to Memorial Sloan Kettering Cancer Center ("MSKCC"). TNS 9.55.3  developed by EGT pursuant to an exclusive license agreement with Sloan Kettering Institute (SKI), will be used for MSKCC's upcoming beta Thalassemia human clinical trial. The trial protocol provides for the "in vitro" treatment of beta-thalassemia patients, offering the prospect for a cure for a chronic condition which would otherwise subject the patient to early death without incurring life-long regular blood transfusions and chelation therapy.

A new definitive agreement between EGT and SKI provides for MSKCC to lead the clinical trials and arrange for drug development partnerships for the treatment of beta-Thalassemia and Sickle Cell Disease, two of the worlds most prevalent and devastating hereditary blood conditions.  

EGT continues its decade's long commitment to cure beta-Thalassemia, also called Cooley's Anemia, through dedicated outreach to patient and research communities around the world. Pat Girondi, EGT founder and CEO, stated, "the pioneering research of SKI's Sadelain team is positioned to deliver the safest and most effective cure for the many millions of patients whose hopes and prayers we have honored with our total dedication." EGT received protocol approval for the upcoming trials by unanimous vote of the Recombinant DNA Advisory Committee of the NIH in 2007, and was granted orphan drug designation by both the FDA and the EMEA. The clinical trial is expected to commence in the fourth quarter of 2011.

Sam Salman, EGT's president said that with "MSKCC and SKI taking the lead in the clinical and developmental activities for TNS 9.55.3, EGT will be able to further progress its pre-clinical programs for its novel drug cancer therapies targeting chronic hormone refractory cancers."  

About Errant Gene Therapeutics, LLC

Errant Gene Therapeutics ("EGT") is a privately held biopharmaceutical company established in 2003. In addition to its ongoing support of gene therapy for the cure of beta-thalassemia and Sickle Cell Anemia, EGT is a pioneer in the emerging field of epigenetics focused on the treatment of deadly hormone  refractory cancers using its patented portfolio of small molecule histone deacetylases inhibitors (HDACi). EGT's lead HDACi, CG-1521, targets Inflammatory Breast Cancer and Hormone Refractory Prostate Cancer.

For more information about EGT and its programs, please visit www.errantgene.com.


'/>"/>
SOURCE Errant Gene Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Transfers Magnetic Beads Business Unit Into its Luxspheres Inc. Subsidiary
2. Scottish Executive Awards Varian Medical Systems Major Contract to Supply Advanced Radiotherapy Equipment to Scotlands Five Cancer Centers
3. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
4. Arkansas Researcher is Exploring MR-Guided Focused Ultrasound as an Adjuvant Therapy to Radiation
5. Mail-Order Pharmacy for New Statin Prescriptions Achieve Better Cholesterol Control in First 3-15 Months of Therapy
6. Provent® Sleep Apnea Therapy Now Available in India
7. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
8. New Release of Elektas Monaco Treatment Planning System Prepares Software for Stereotactic Radiation Therapy
9. Latest Releases of Elektas XiO Planning and Focal Contouring Systems Designed to Increase Efficiency in Planning Therapy for Patients with Cancer
10. Dehaier Opens First Oxygen Filling Facility and First Service Center for Home Oxygen Therapy Service in Beijing
11. PhotoMedexs Itching to Win Contest Offers Free Phototherapy Treatments With the XTRAC Laser to Deserving Psoriasis Patients Nationwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
Breaking Medicine Technology:
(Date:5/19/2017)... CA (PRWEB) , ... May 19, 2017 , ... ... of the 2017 class of Beckman Young Investigators: , Victor Acosta, Ph.D. - ... - Cornell University, Dan Fu, Ph.D. - University of Washington, Erik Grumstrup, Ph.D. ...
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon on the frontline ... prostate cancer screenings. Early detection of the disease, he says, can make a world ... Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task ...
(Date:5/19/2017)... ... 18, 2017 , ... CloSYS products which are marketed as the gentle giants ... mouth and gum health, which is linked to one’s overall health. Since 1991 when ... the powerful ways in which CloSYS products immediately helped eliminate bad breath as well ...
(Date:5/19/2017)... ... May 18, 2017 , ... Somnoware, a leading provider of digital health technology, ... dispense CPAP devices and supplies, such as machines, filters, tubing, and masks. Using this ... Device registration for daily usage data is automated, and a DME order is created ...
(Date:5/18/2017)... ... May 18, 2017 , ... Originally launched to market as ... Learning Tab. Due to the rapid expansion of their product line, the company believed ... product. Now, the HighQ brand will be any tablet product sold by EPIK ...
Breaking Medicine News(10 mins):